Abstract
The second generation anticonvulsants are generally considered to be the nonbenzodiazepine antiepileptic medications approved by the US Food and Drug Administration (FDA) after 1967 when valproic acid was marketed. There was a surge of newer anticonvulsant pharmaceuticals approved for clinical use, starting with vigabatrin in the late 1980s and continued throughout the 1990s (oxcarbazine, lamotrigine, gabapentin, felbamate, topiramate, tiagabine, fosphenytoin, levetiracetam, and zonisamide). Discontinuation of some of these pharmaceuticals in the USA and other countries has already occurred due to the decisions of the manufacturer, FDA, and other regulatory authorities, secondary to side effects and clinicians choosing more efficacious options.
Similar content being viewed by others
References
Klein-Schwartz W, Shepherd JG, Gorman S, Dahl B. Characterization of gabapentin overdose using a poison center case series. J Toxicol Clin Toxicol. 2003;41(1):11–5.
Verma A, St Clair EW, Radtke RA. A case of sustained massive gabapentin overdose without serious side effects. Ther Drug Monit. 1999;21(6):615–7.
Ghinea N, Lipworth W, Kerridge I. Evidence, regulation and “rational” prescribing: the case of gabapentin for neuropathic pain. J Eval Clin Pract. 2015;21(1):28–33. doi:10.1111/jep.12223.
Lexicomp. Gabapentin. Hudson, ohio: Lexi-comp, inc.; august 10, 2015.
Sukumaran S, Herbert J, Tracey J, Delanty N. Safety of newer generation anti-epileptic drugs in non-accidental overdose: an Irish population study. Seizure. 2005;14(3):151–6. doi: S1059131104000457 [pii].
Splinter M. Pharmacokinetic properties of new antiepileptic drugs. J Pharm Pract. 2005;18:444–60.
Wills B, Reynolds P, Chu E, et al. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10(3):254–60. doi:10.1007/s13181-014-0384-5.
Fischer JH, Barr AN, Rogers SL, Fischer PA, Trudeau VL. Lack of serious toxicity following gabapentin overdose. Neurology. 1994;44(5):982–3.
Middleton O. Suicide by gabapentin overdose. J Forensic Sci. 2011;56(5):1373–5. doi:10.1111/j.1556-4029.2011.01798.x.
Jones H, Aguila E, Farber HW. Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis. Ann Intern Med. 2002;137(1):74. doi: 200207020–00029 [pii].
Fujii H, Goel A, Bernard N, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013;80(17):1565–70. doi:10.1212/WNL.0b013e31828f18c1.
Fleurat M, Smollin C. Case files of the university of California san Francisco medical toxicology fellowship: lamotrigine toxicity. J Med Toxicol. 2012;8(1):52–8. doi:10.1007/s13181-012-0210-x.
Chavez P, Casso Dominguez A, Herzog E. Evolving electrocardiographic changes in lamotrigine overdose: a case report and literature review. Cardiovasc Toxicol. 2014. doi:10.1007/s12012-014-9300-0.
Thundiyil JG, Anderson IB, Stewart PJ, Olson KR. Lamotrigine-induced seizures in a child: case report and literature review. Clin Toxicol (Phila). 2007;45(2):169–72. doi: 770469171 [pii].
Algahtani HA, Aldarmahi AA, Al-Rabia MW, Almalki WH, Bryan Young G. Generalized myoclonus and spasticity induced by lamotrigine toxicity: a case report and literature review. Clin Neuropharmacol. 2014;37(2):52–4. doi:10.1097/WNF.0000000000000020.
Lexicomp. Lamotrigine. Hudson, ohio: Lexi-comp, inc.; august 10, 2015.
French LK, McKeown NJ, Hendrickson RG. Complete heart block and death following lamotrigine overdose. Clin Toxicol (Phila). 2011;49(4):330–3. doi:10.3109/15563650.2011.572555.
Strimel WJ, Woodruff A, Cheung P, Kirmani BF, Stephen Huang SK. Brugada-like electrocardiographic pattern induced by lamotrigine toxicity. Clin Neuropharmacol. 2010;33(5):265–7. doi:10.1097/WNF.0b013e3181e8ac66.
Herold TJ. Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder. CJEM. 2006;8(5):361–4. doi: DDBBDEB07E9741FBB2E2320DB9DFFC62 [pii].
Dinnerstein E, Jobst BC, Williamson PD. Lamotrigine intoxication provoking status epilepticus in an adult with localization-related epilepsy. Arch Neurol. 2007;64(9):1344–6. doi: 64/9/1344 [pii].
Amante MF, Filippini AV, Cejas N, Lendoire J, Imventarza O, Parisi C. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann Hepatol. 2009;8(1):75–7. doi: 878839 [pii].
Roquin G, Peres M, Lerolle N, et al. First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis. Ann Pharmacother. 2010;44(12):1998–2000. doi: 10.1345/aph.1P350.
Wade JF, Dang CV, Nelson L, Wasserberger J. Emergent complications of the newer anticonvulsants. J Emerg Med. 2010;38(2):231–7. doi:10.1016/j.jemermed.2008.03.032.
Overstreet K, Costanza C, Behling C, Hassanin T, Masliah E. Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. Dig Dis Sci. 2002;47(9):1921–5.
Makin AJ, Fitt S, Williams R, Duncan JS. Fulminant hepatic failure induced by lamotrigine. BMJ. 1995;311(7000):292.
Mycyk MB, Carlson A. Toxicologic causes of giggling. J Emerg Med. 2001;21(2):195. doi: S0736467901003687 [pii].
Nwogbe B, Ferie J, Smith H, Gunawardena I, Dhatariya K. Significant lamotrigine overdose associated with acute pancreatitis. J R Soc Med. 2009;102(3):118–9. doi:10.1258/jrsm.2009.080314.
Lofton AL, Klein-Schwartz W. Evaluation of toxicity of topiramate exposures reported to poison centers. Hum Exp Toxicol. 2005;24(11):591–5.
Moore PW, Donovan JW, Burkhart KK, Haggerty D. A case series of patients with lamotrigine toxicity at one center from 2003 to 2012. Clin Toxicol (Phila). 2013;51(7):545–9. doi:10.3109/15563650.2013.818685.
Schwartz MD, Geller RJ. Seizures and altered mental status after lamotrigine overdose. Ther Drug Monit. 2007;29(6):843–4. doi:10.1097/FTD.0b013e31815bf239.
Briassoulis G, Kalabalikis P, Tamiolaki M, Hatzis T. Lamotrigine childhood overdose. Pediatr Neurol. 1998;19(3):239–42. doi: S0887-8994(98)00050-2 [pii].
O'Donnell J, Bateman DN. Lamotrigine overdose in an adult. J Toxicol Clin Toxicol. 2000;38(6):659–60.
Miller MA, Levsky ME. Choreiform dyskinesia following isolated lamotrigine overdose. J Child Neurol. 2008;23(2):243. doi:10.1177/0883073807308693.
Reimers A, Reinholt G. Acute lamotrigine overdose in an adolescent. Ther Drug Monit. 2007;29(5):669–70. doi:10.1097/FTD.0b013e318074dc8a.
Eren Cevik S, Tasyurek T, Guneysel O. Intralipid emulsion treatment as an antidote in lipophilic drug intoxications. Am J Emerg Med. 2014;32(9):1103–8. doi:10.1016/j.ajem.2014.05.019.
Daana M, Nevo Y, Tenenbaum A, Taustein I, Berger I. Lamotrigine overdose in a child. J Child Neurol. 2007;22(5):642–4. doi: 22/5/642 [pii].
Ouellet G, Tremblay L, Marleau D. Fulminant hepatitis induced by lamotrigine. South Med J. 2009;102(1):82–4. doi:10.1097/SMJ.0b013e3181878b95.
Castanares-Zapatero D, Wittebole X, Huberlant V, Morunglav M, Hantson P. Lipid emulsion as rescue therapy in lamotrigine overdose. J Emerg Med. 2012;42(1):48–51. doi:10.1016/j.jemermed.2010.11.055.
Nogar JN, Minns AB, Savaser DJ, Ly BT. Severe sodium channel blockade and cardiovascular collapse due to a massive lamotrigine overdose. Clin Toxicol (Phila). 2011;49(9):854–7. doi:10.3109/15563650.2011.617307.
Chavez P, Casso Dominguez A, Herzog E. Evolving electrocardiographic changes in lamotrigine overdose: a case report and literature review. Cardiovasc Toxicol. 2015;15(4):394–8. doi:10.1007/s12012-014-9300-0.
Sirianni AJ, Osterhoudt KC, Calello DP, et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. Ann Emerg Med. 2008;51(4):412–5, 415.e1. doi: S0196-0644(07)00717-2 [pii].
Presley JD, Chyka PA. Intravenous lipid emulsion to reverse acute drug toxicity in pediatric patients. Ann Pharmacother. 2013;47(5):735–43. doi:10.1345/aph.1R666.
Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT. EUROCAT antiepileptic drug working group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22. doi:10.1212/01.wnl.0000316194.98475.d8.
Grunewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:154–60. doi: EPI329 [pii].
Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G. The adverse event profile of levetiracetam: a meta-analysis on children and adults. Seizure. 2015;31:49–55. doi:10.1016/j.seizure.2015.07.004.
Trinka E, Hofler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75(13):1499–521. doi:10.1007/s40265-015-0454-2.
Zheng F, Du C, Wang X. Levetiracetam for the treatment of status epilepticus. Expert Rev Neurother. 2015;15(10):1113–21. doi:10.1586/14737175.2015.1088785.
Lexicomp. Levetiracetam. Hudson, ohio: Lexi-comp, inc.; august 10, 2015.
Barrueto Jr F, Williams K, Howland MA, Hoffman RS, Nelson LS. A case of levetiracetam (keppra) poisoning with clinical and toxicokinetic data. J Toxicol Clin Toxicol. 2002;40(7):881–4.
Awaad Y. Accidental overdosage of levetiracetam in two children caused no side effects. Epilepsy Behav. 2007;11(2):247. doi: S1525-5050(07)00186-2 [pii].
Bodmer M, Monte AA, Kokko J, Yin S. Safety of non-therapeutic levetiracetam ingestions – a poison center based study. Pharmacoepidemiol Drug Saf. 2011;20(4):366–9. doi:10.1002/pds.2113.
Larkin TM, Cohen-Oram AN, Catalano G, Catalano MC. Overdose with levetiracetam: a case report and review of the literature. J Clin Pharm Ther. 2013;38(1):68–70. doi:10.1111/j.1365-2710.2012.01361.x.
Chua-Tuan JL, Cao D, Iwanicki JL, Hoyte CO. Cardiac sodium channel blockade after an intentional ingestion of lacosamide, cyclobenzaprine, and levetiracetam: case report. Clin Toxicol (Phila). 2015;53(6):565–8. doi:10.3109/15563650.2015.1040157.
Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48(6):1111–6. doi: EPI1032 [pii].
Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25(3):347–63.
Anand JS, Chodorowski Z, Wisniewski M. Seizures induced by topiramate overdose. Clin Toxicol (Phila). 2007;45(2):197. doi: 770465982 [pii].
Wisniewski M, Lukasik-Glebocka M, Anand JS. Acute topiramate overdose – clinical manifestations. Clin Toxicol (Phila). 2009;47(4):317–20. doi:10.1080/15563650601117954.
Lexicomp. Topiramate. Hudson, ohio: Lexi-comp, inc.; august 10, 2015.
Lynch MJ, Pizon AF, Siam MG, Krasowski MD. Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. J Med Toxicol. 2010;6(2):135–8. doi:10.1007/s13181-010-0065-y.
Brandt C, Elsner H, Furatsch N, et al. Topiramate overdose: a case report of a patient with extremely high topiramate serum concentrations and nonconvulsive status epilepticus. Epilepsia. 2010;51(6):1090–3. doi:10.1111/j.1528-1167.2009.02395.x.
Meral C, Aydinoz S. Simple dosage inaccuracy might be the cause of serious side effects of topiramate. Clin Toxicol (Phila). 2009;47(7):691. doi:10.1080/15563650903158888.
Fakhoury T, Murray L, Seger D, McLean M, Abou-Khalil B. Topiramate overdose: clinical and laboratory features. Epilepsy Behav. 2002;3(2):185–9. doi: S1525505002903392 [pii].
McDonald P, McLean M, Thomas R. Topiramate has acute proconvulsant and delayed anticonvulsant effects on cultured central neurons and a mouse seizure model. Neurology. 2001;56:A332.
Brar B, Glazer JP, Franco K, Edwards T. Acute mental status changes with topiramate. J Am Acad Child Adolesc Psychiatry. 2005;44(8):725. doi: S0890-8567(09)61731-7 [pii].
Chung AM, Reed MD. Intentional topiramate ingestion in an adolescent female. Ann Pharmacother. 2004;38(9):1439–42. doi:10.1345/aph.1D572.
Lin G, Lawrence R. Pediatric case report of topiramate toxicity. Clin Toxicol (Phila). 2006;44(1):67–9.
Langman LJ, Kaliciak HA, Boone SA. Fatal acute topiramate toxicity. J Anal Toxicol. 2003;27(5):323–4. doi: NO_DOI.
French JA, Pedley TA. Clinical practice. Initial management of epilepsy. N Engl J Med. 2008;359(2):166–76. doi:10.1056/NEJMcp0801738.
Alsaad AM, Chaudhry SA, Koren G. First trimester exposure to topiramate and the risk of oral clefts in the offspring: a systematic review and meta-analysis. Reprod Toxicol. 2015;53:45–50. doi:10.1016/j.reprotox.2015.03.003.
Nagel TR, Schunk JE. Felbamate overdose: a case report and discussion of a new antiepileptic drug. Pediatr Emerg Care. 1995;11(6):369–71.
Meier KH, Olson KR, Olson JL. Acute felbamate overdose with crystalluria. Clin Toxicol (Phila). 2005;43(3):189–92.
Rengstorff DS, Milstone AP, Seger DL, Meredith TJ. Felbamate overdose complicated by massive crystalluria and acute renal failure. J Toxicol Clin Toxicol. 2000;38(6):667–9.
Sparagana SP, Strand WR, Adams RC. Felbamate urolithiasis. Epilepsia. 2001;42(5):682–5. doi: epi32500 [pii].
O'Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology. 1996;46(5):1457–9.
Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology. 1995;45(3 Pt 1):456–60.
Malissin I, Baud FJ, Deveaux M, Champion S, Deye N, Megarbane B. Fatal lacosamide poisoning in relation to cardiac conduction impairment and cardiovascular failure. Clin Toxicol (Phila). 2013;51(4):381–2. doi: 10.3109/15563650.2013.778993 .
Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010;18(3):322–4. doi: 10.1016/j.yebeh.2010.04.043 .
Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav. 2011;20(4):725–7. doi: 10.1016/j.yebeh.2011.02.006 .
Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a phase III open-label extension trial. Epilepsia. 2012;53(3):521–8. doi: 10.1111/j.1528-1167.2012.03407.x .
Forbes RA, Kalra H, Hackett LP, Daly FF. Deliberate self-poisoning with tiagabine: an unusual toxidrome. Emerg Med Australas. 2007;19(6):556–8. doi: EMM973 [pii].
Leach JP, Brodie MJ. Tiagabine. Lancet. 1998;351(9097):203–7. doi: S0140-6736(97)05035-6 [pii].
Fulton JA, Hoffman RS, Nelson LS. Tiagabine overdose: a case of status epilepticus in a non-epileptic patient. Clin Toxicol (Phila). 2005;43(7):869–71.
Spiller HA, Winter ML, Ryan M, et al. Retrospective evaluation of tiagabine overdose. Clin Toxicol (Phila). 2005;43(7):855–9.
Kazzi ZN, Jones CC, Morgan BW. Seizures in a pediatric patient with a tiagabine overdose. J Med Toxicol. 2006;2(4):160–2.
Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005;46(1):31–41. doi: EPI14704 [pii].
Hofer KE, Trachsel C, Rauber-Luthy C, Kupferschmidt H, Kullak-Ublick GA, Ceschi A. Moderate toxic effects following acute zonisamide overdose. Epilepsy Behav. 2011;21(1):91–3. doi: 10.1016/j.yebeh.2011.02.023 .
Ijiri Y, Inoue T, Fukuda F, et al. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia. 2004;45(8):924–7. doi: 10.1111/j.0013-9580.2004.30603.x .
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition
Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition
-
I
Evidence obtained from at least one properly randomized controlled trial.
-
II-1
Evidence obtained from well-designed controlled trials without randomization.
-
II-2
Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.
-
II-3
Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.
-
III
Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this entry
Cite this entry
Emswiler, M.P., Cumpston, K.L. (2016). Second Generation Anticonvulsants: Gabapentin, Lamotrigene, Leveticetam, and Topiramate. In: Brent, J., Burkhart, K., Dargan, P., Hatten, B., Megarbane, B., Palmer, R. (eds) Critical Care Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-319-20790-2_41-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-20790-2_41-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Online ISBN: 978-3-319-20790-2
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences
Publish with us
Chapter history
-
Latest
Second Generation Anticonvulsants: Gabapentin, Lamotrigine, Levetiracetam, and Topiramate- Published:
- 12 January 2017
DOI: https://doi.org/10.1007/978-3-319-20790-2_41-2
-
Original
Second Generation Anticonvulsants: Gabapentin, Lamotrigene, Leveticetam, and Topiramate- Published:
- 18 October 2016
DOI: https://doi.org/10.1007/978-3-319-20790-2_41-1